AVEO Pharmaceuticals Revenue 2011-2026 | AVEO

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue AVEO Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
42.3 M	6.02 M	28.8 M	5.41 M	7.58 M	2.52 M	19 M	18.1 M	1.29 M	19.3 M	165 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
165 M	1.29 M	28.7 M

Quarterly Revenue AVEO Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	30.4 M	-	20.9 M	17.6 M	15.2 M	7.56 M	1.92 M	886 K	20 M	20 M	20 M	764 K	25.7 M	703 K	1.61 M	1.48 M	2.47 M	433 K	1.03 M	82 K	4.61 M	351 K	2.53 M	127 K	992 K	193 K	1.2 M	3.6 M	15.2 M	134 K	134 K	115 K	873 K	1.85 M	15.3 M	323 K	323 K	324 K	323 K	15.5 M	1.02 M	1.88 M	860 K	1.1 M	3.58 M	26.6 M	134 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
134 M	82 K	9.16 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
AbCellera Biologics ABCL	75.1 M	$ 3.55	-0.28 %	$ 1.06 B	Canada
Adagene ADAG	10.2 M	$ 3.91	-2.01 %	$ 220 M	China
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
AC Immune SA ACIU	27.3 M	$ 3.32	6.07 %	$ 229 M	Schweiz
I-Mab IMAB	88 M	-	-	$ 866 M	China
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
ADC Therapeutics SA ADCT	2.34 M	$ 4.11	-2.61 %	$ 105 M	Schweiz
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Aptorum Group Limited APM	912 K	$ 0.79	0.04 %	$ 4.31 M	China
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
argenx SE ARGX	36.4 M	$ 706.03	0.39 %	$ 25 B	Niderland
Alterity Therapeutics Limited ATHE	109 K	$ 3.34	-7.48 %	$ 8.04 B	Australia
Ascendis Pharma A/S ASND	720 M	$ 228.06	-1.28 %	$ 5 B	Danmark
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Can-Fite BioPharma Ltd. CANF	853 K	$ 3.43	-4.19 %	$ 7.46 B	Israel
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Anika Therapeutics ANIK	167 M	$ 14.51	1.04 %	$ 213 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Arcturus Therapeutics Holdings ARCT	82 M	$ 6.39	-3.62 %	$ 175 M	Israel
BioNTech SE BNTX	482 M	$ 94.86	4.77 %	$ 27.2 B	Germany
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Burford Capital Limited BUR	330 M	$ 8.28	2.86 %	$ 1.34 B	Britain
Athersys ATHX	5.51 M	-	3.77 %	$ 22.4 M	USA
Actinium Pharmaceuticals ATNM	81 K	$ 1.14	2.7 %	$ 34.3 M	USA
Autolus Therapeutics plc AUTL	242 K	$ 1.51	-	$ 385 M	Britain
Atea Pharmaceuticals AVIR	351 M	$ 6.13	1.32 %	$ 500 M	USA
Equillium EQ	36.1 M	$ 2.15	-7.33 %	$ 74.7 M	USA